MGF / PEG-MGF

Mechano Growth Factor · IGF-1Ec · PEGylated MGF · C-domain peptide

"The IGF-1 splice variant your muscles produce in response to mechanical stress — a localised repair signal with a ~5 minute half-life in its native form. PEG-MGF pegylates it to extend activity to several days. Acts through a receptor distinct from IGF-1R, driving satellite cell activation at the site of damage rather than systemically. The bodybuilder's tissue repair peptide."

Type

IGF-1Ec splice variant · 24 aa C-terminal fragment

Half-life

~5 min (MGF) · days (PEG-MGF)

Status

UK: not illegal to buy or possess · WADA: prohibited at all times · US FDA: removed from Cat 2 Apr 2026 · PCAC review by Feb 2027

Mechanism

Non-IGF-1R pathway · satellite cell activation

Protocol summary

PEG-MGF dose

100–400 mcg per injection

Frequency

2–3× weekly post-workout

Cycle

8–10 weeks, 4+ weeks off

Community-reported

200–400 mcg PEG-MGF · SubQ post-workout · 2–3× weekly

Often stacked with BPC-157 + TB-500 for injury recovery

How we read the evidence

IGF-1 splice variant naturally released by mechanical muscle stress · solid satellite-cell preclinical data · zero formal human trials · marketing exceeds evidence base

Animal evidence

Substantial preclinical foundation. MGF (mechano growth factor, also called IGF-1Ec) is a splice variant of the IGF-1 gene with a unique E-domain sequence (49bp insert in humans) — distinct from the better-known IGF-1Ea isoform. Naturally released from skeletal muscle in response to mechanical overload (resistance training, eccentric load, injury). Mechanism: activates muscle satellite cells, drives proliferation and fusion into existing fibres, accelerates repair. Native MGF has a half-life of only minutes; PEGylation (PEG-MGF) extends this to 48–72 hours. Ates et al. 2007 (Pubmed 21354439) demonstrated that the MGF-24aa-E peptide alone significantly increases satellite cell proliferative life span and fusion potential in human muscle cell cultures — without the oncogenic concerns of full IGF-1.

Community & clinical practice

Community protocols converge on PEG-MGF 100–400 mcg SubQ or IM 2–3× weekly post-workout, in 8–10 week cycles followed by 4+ weeks off. Many users inject directly into the trained muscle group to bias local satellite cell activation, with bilateral split for symmetric muscle groups. Beginners start at 150–200 mcg per injection. The PEGylation means daily dosing is unnecessary — twice weekly is the typical maintenance schedule. Native (non-PEGylated) MGF is rarely used now because the half-life is too short for practical dosing. Often stacked with IGF-1 LR3 in a damage-then-rebuild rotation, though the stacking evidence is anecdotal.

Human trial data

No formal human clinical trials of synthetic MGF or PEG-MGF have been completed. The mechanism evidence comes from cell culture work (Ates 2007, others) and animal injury models (Hong Kong Polytechnic 2018 macrophage resolution work in mouse skeletal muscle injury). The community use base is entirely extrapolated from preclinical work plus the underlying IGF-1 trial framework — but MGF is biologically distinct from IGF-1 and the extrapolation is imperfect. Marketing claims of dramatic localised hypertrophy and recovery effects exceed what trial-level evidence supports.

Regulatory status

Not approved by any regulatory agency. FDA has explicitly warned about safety risks from the limited research data on MGF/PEG-MGF use. Sourcing via research-peptide vendors with significant purity variation. WADA-banned for tested athletes (peptide hormones and growth factors category). The PEG modification and recombinant production process introduces additional purity considerations beyond standard peptide manufacturing.

Convergence

MGF has a real and elegant biology — naturally released by mechanical stress, drives the satellite cell repair pathway, distinct from systemic IGF-1. Preclinical evidence supports the mechanism. But no formal human trials exist, the community marketing significantly exceeds evidence, and FDA has flagged safety data as inadequate. Standard community protocol: PEG-MGF 100–400 mcg 2–3× weekly post-workout, 8–10 weeks on, 4+ weeks off, often into the trained muscle. Pep IQ flags this honestly: the mechanism is plausible, the dose-response is unvalidated, and outcomes claimed by community users are difficult to separate from training and nutrition contributions. If you're going to use this, accept that you're running uncharted human pharmacology with only animal-model data behind you.

Origin & Background

The muscle's own damage repair signal

Mechano Growth Factor (MGF) is an alternatively spliced isoform of the IGF-1 gene — specifically the IGF-1Ec isoform produced when the IGF-1 gene is spliced in response to mechanical stress or tissue damage. When you train, tear muscle fibres, or sustain an injury, the local tissue upregulates this specific splice variant to initiate repair. It is the body's own localised muscle repair signal, distinct from the systemic IGF-1 produced by the liver in response to GH.

The critical distinction from IGF-1 LR3: MGF acts primarily through a receptor separate from IGF-1R — likely involving the extracellular signal domain of the E-peptide — and drives satellite cell activation through the MAPK-Erk1/2 pathway independently of the PI3K/Akt pathway that dominates IGF-1R signalling. This means MGF and IGF-1 are not redundant — they stimulate different aspects of the repair and hypertrophy process and can be used together synergistically.

The problem with native MGF is its ~5 minute half-life — almost useless for systemic administration. PEG-MGF (PEGylated MGF) conjugates polyethylene glycol (PEG) chains to the peptide, dramatically increasing plasma half-life to several days. This enables systemic administration with once-weekly dosing and produces sustained satellite cell activation throughout the body rather than locally. PEG-MGF is the practical form most community users employ; native MGF is used by some for local site injections immediately post-workout.

Science & Mechanism

Satellite cells, MAPK pathway, and PEGylation

Mechanism of Action

Mechanical stress-induced splicing: During exercise or injury, the IGF-1 gene is alternatively spliced to produce the IGF-1Ec mRNA. The Ec domain (E-peptide) is MGF's unique C-terminal extension — a 24 amino acid sequence that is specifically cleaved from the rest of the IGF-1Ec protein and acts as a separate signalling molecule. This E-peptide fragment is what the synthetic MGF peptide replicates.

Satellite cell activation via MAPK-Erk1/2: MGF activates quiescent muscle satellite cells — the stem cells that fuse with existing fibres to enable hypertrophy and repair — through the MAPK-Erk1/2 pathway, independently of IGF-1R. This initial activation step precedes IGF-1-mediated differentiation, making MGF and IGF-1/LR3 genuinely complementary: MGF wakes up satellite cells; IGF-1 drives their proliferation and differentiation into mature muscle.

Local vs systemic delivery: Native MGF injected at the site of muscle damage or immediately adjacent to trained muscles acts locally before rapid clearance. PEG-MGF distributes systemically and activates satellite cells throughout the body. The choice depends on whether localised injury repair (native MGF, site injection) or broad anabolic stimulus (PEG-MGF) is the goal.

PEGylation extends half-life: Conjugation of PEG chains to MGF sterically shields the peptide from proteolytic enzymes and renal clearance, extending plasma half-life from ~5 minutes to several days depending on the PEG molecular weight. This transforms an impractical research tool into a usable once-weekly SubQ compound.

Non-redundancy with IGF-1 LR3: Because MGF acts through a different receptor and pathway than IGF-1R, the two have additive effects on satellite cell biology. Community protocols frequently combine PEG-MGF (satellite cell activation) with IGF-1 LR3 (proliferation and differentiation) to target both arms of the hypertrophy cascade simultaneously.

Things to know

Risks & considerations

Moderate

Proliferative risk over extended use — prolonged satellite cell activation via MAPK-Erk1/2 at supraphysiological levels raises theoretical concern about uncontrolled cellular proliferation in susceptible tissues. Cycle to 4–6 weeks maximum. Contraindicated with active or recent malignancy.

Mild

Injection site reactions — local redness and swelling, particularly with site injections of native MGF adjacent to muscle. Transient and self-resolving.

Unknown

PEG accumulation — PEG chains from PEGylated compounds can accumulate in tissues with prolonged use. The clinical significance at PEG-MGF doses is unknown. Avoid continuous long-term use.